Clinical diagnosis, treatment and prognosis of neuroendocrine breast cancer

关燕; 王晓文; 张明帅; 张晨光; 欧江华

doi:10.3969/j.issn.1007-3969.2014.06.008

您当前的位置：

首页 >

文章列表页 >

Clinical diagnosis, treatment and prognosis of neuroendocrine breast cancer

更新时间：2025-12-31

- Clinical diagnosis, treatment and prognosis of neuroendocrine breast cancer
- China Oncology Vol. 24, Issue 6, Pages: 438-445(2014)
- 作者机构：
  
  新疆医科大学附属肿瘤医院乳腺外科,新疆,乌鲁木齐,830011
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2014.06.008
  CLC：
- Published Online：29 July 2014，
  
  Published：29 July 2014
- 稿件说明：
移动端阅览
关燕,王晓文,张明帅,张晨光,欧江华. 乳腺神经内分泌癌的临床诊治及预后分析[J]. 中国癌症杂志, 2014, 24(6): 438-445.

关燕, 王晓文, 张明帅, et al. Clinical diagnosis, treatment and prognosis of neuroendocrine breast cancer[J]. China Oncology, 2014, 24(6): 438-445.
关燕,王晓文,张明帅,张晨光,欧江华. 乳腺神经内分泌癌的临床诊治及预后分析[J]. 中国癌症杂志, 2014, 24(6): 438-445. DOI： 10.3969/j.issn.1007-3969.2014.06.008.

关燕, 王晓文, 张明帅, et al. Clinical diagnosis, treatment and prognosis of neuroendocrine breast cancer[J]. China Oncology, 2014, 24(6): 438-445. DOI： 10.3969/j.issn.1007-3969.2014.06.008.

摘要

背景与目的：近年来国内外对乳腺神经内分泌癌(neuroendocrine breast cancer，NEBC)这一临床上罕见类型的乳腺癌开展了越来越多的临床研究，但目前检索到的国内外有关NEBC的文献大多是病例报道，大规模的临床研究少见，报道的病例数不多，大多数研究在流行病学特点、诊断、治疗及预后方面的报道存在差异，需要更多的研究提高对NEBC的总体认识和诊治水平。本文主要探讨NEBC的临床诊断、治疗以及预后情况。方法：回顾分析了新疆医科大学附属肿瘤医院2004年１月—2013年6月收治的25例经病理明确诊断为NEBC患者的临床资料并对其随访。结果：25例NEBC患者平均发病年龄58.2岁，临床特点及影像学检查无特征性表现，免疫组化中雌激素受体(estrogen receptor，ER)和孕激素受体(progesterone receptor，PR)阳性率分别为76%和64%，无1例出现原癌基因人表皮生长因子受体2(human epidermal growth factor receptor-2，HER-2)强阳性，全部患者随访9~115个月，1、2、5年的总生存率(overall survival，OS)分别为100%、95%、88%，无病生存率(disease-free survival，DFS)为96%、90%、78%。结论：本组NEBC患者的发病年龄低于国外，术后综合治疗方案的选择仍需进一步研究，发病年龄、肿瘤大小、术后病理分期可能与患者的预后相关。有关NEBC的治疗及预后还需要大样本长时间的随访观察。

Abstract

Background and purpose: In recent years

more and more clinical researches on the neuroendocrine carcinoma of the breast were carried out at home and abroad. Although there are quite a lot of the retrieved documents of NEBC at home and abroad

but large-scale reports are rare

besides

the epidemiology

diagnosis

treatment and prognosis were different; more research are needed to analyze NEBC. This paper mainly discussed the NEBC clinical diagnosis

treatment and prognosis. Methods: A retrospective analysis was carried out

25 cases of Tumor Hospital Affiliated to Xinjiang Medical University from Jan. 2004 to Jun. 2013 were pathologically diagnosed as NEBC by clinical data and the follow-up. Results: The average age of 25 NEBC patients was 58.2 years old

without clinical and imaging characteristic features

immunohistochemistry staining showed that

the estrogen receptor (ER) and progesterone receptor (PR) positive rates were 76% and 64%. No one showed HER-2 strong positive. The followup was 9-115 months. Besides

2- and 5-year overall survival (OS) rates were 100%

95% and 88%

the disease-free survival (DFS) rates were 96%

90% and 78%. Conclusion: The age of the patients with NEBC in this study was lower than the data abroad. Age

tumor size

pathological staging may be related to the prognosis of NEBC

and postoperative comprehensive treatment options need further study.

关键词

Keywords

references

Views

2676

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical and pathological prognostic analysis of 62 patients with fallopian tube carcinoma

Clinicopathologic features of SMARCA4-deficient pulmonary malignant tumor with an emphasis on the prognosis

Treatment strategies and prognostic analysis of 87 patients with salivary duct carcinoma: a retrospective cohort study

Impact of radiation-induced lymphopenia on prognosis in patients with limited-stage small cell lung cancer: a cohort study

MITF expression in acral melanoma tissues and its association with clinical, pathological characteristics and prognosis

Related Author

黄建琴

肖银平

朱芝玲

CHANG Kesheng

SHAO Jin

ZHANG Qi

LIU Yifei

Ximei ZHANG

Related Institution

复旦大学附属妇产科医院中西医结合科

复旦大学附属妇产科医院病理科

Department of Pathology, Wuxi Second People’s Hospital

Department of Pathology, Affiliated Hospital of Nantong University

Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Malignant Tumors

AI问答

⁰